Used in research and therapeutic development targeting the CXCL12/CXCR4 signaling pathway, this antibody helps modulate cell migration, particularly in cancer and inflammatory diseases. It is applied in studies involving tumor microenvironment, metastasis inhibition, and stem cell mobilization. The antibody has been utilized in preclinical models to block CXCL12-mediated recruitment of immune and cancer cells, showing potential in enhancing the efficacy of immunotherapies and chemotherapy. It also supports research in autoimmune diseases and tissue injury repair by regulating inflammatory cell trafficking.